Beam Therapeutics Inc. BEAM incurred a loss of $1.17 per share in the third quarter of 2024, wider than the Zacks Consensus Estimate of a loss of $1.13. The company had recorded a loss of $1.22 per share...
This article delves into three biotech stocks held in Cathie Wood's ARKK ETF that analysts expect to double in value. Investors looking to add exposure to promising biotech opportunities, with a preference...
JPMorgan Chase becomes the latest institution in the company's bull pen.
March S&P 500 E-Mini futures (ESH24) are down -0.04%, and March Nasdaq 100 E-Mini futures (NQH24) are up +0.11% this morning as market participants braced for the Federal Reserve’s first monetary policy...
Analysts have high hopes for these three innovation companies in 2024.
Even if Wall Street is wrong about these stocks in the new year, Cathie Wood could still be right about them over the long run.